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Abstract
Background: The major allergens in Parietaria pollen, Par j 1 and Par j 2, have
been identified as lipid transfer proteins. The family of the Par j 1 allergens is
composed of two isoforms, which differ by the presence of a 37 amino acid pep-
tide (Par37) exclusive to the Par j 1.0101 isoform. The goal of this study was to
elucidate the biological properties of the Par37 peptide.
Methods: In silico analysis, spectrofluorimetric experiments and in vitro cell cul-
ture assays were used to identify the biological properties of Par37. In addition, a
mouse model of sensitization was used to study the influence of Par37 in the mur-
ine immune response.
Results: In silico analysis predicted that Par37 displays characteristics of a host
defence peptide. Spectrofluorimetric analysis, real-time PCR and ELISA assays
demonstrated that Par37 possesses an LPS-binding activity influencing cell signal-
ling in vitro. In RAW264.7 cells, LPS-induced IL-6 and TNF-a transcription and
translation were inhibited after preincubation with Par37. Consistent with these
data, inhibition of IFN-c secretion was observed in murine spleen cells and in
human PBMC. Finally, mice immunized with the two Par j 1 isoforms differing
in the presence or absence of the Par37 peptide showed different immunological
behaviours in vivo.
Conclusions: This study demonstrates that the Par j 1.0101 allergen displays LPS-
binding activity due to the presence of a 37 amino acid COOH-terminal region
and that this region is capable of influencing cytokine and antibody responses
in vitro and in vivo.
Type I hypersensitivity is the clinical manifestation of an
aberrant immune response against protein molecules, com-
monly known as allergens, which are potent inducers of
immunoglobulin E (IgE) synthesis (1).
Although a large number of allergens have been charac-
terized in recent years, there are little data concerning the
functional features that these molecules have in common
and could explain their ability to provoke powerful IgE
antibody responses (2). For a large number of allergens,
their biological functions have been determined (3), show-
ing that some of their activities can contribute to their al-
lergenicity [see (4) for a review]. In the last few years,
there has been some evidence that allergenicity may reside
in the ability to activate different innate immune pathways
at the mucosal surface, suggesting that this early event
may represent a crucial step for the pathological onset of
the disease (5). One example is the group 2 major house
dust mite (HDM) allergens, which show structural homolo-
gies to MD-2 (6,7) and the Der p 7 HDM allergen that
presents structural homology to another family of innate
immune proteins (LPS-binding proteins) that bind various
hydrophobic ligands and are involved in the TLR4 path-
way (8).
However, the reason why some proteins tend to function
as allergens in genetically predisposed subjects is a question
that remains fundamentally unanswered and is of paramount
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importance for understanding the mechanism involved in the
onset of the allergic reaction.
In plants, lipid transfer proteins 1 (LTP1) display a wide
range of functional properties (9–13). In the last decade,
LTPs from pollen and plant derived foods have attracted
new interest as major IgE inducers in humans (see (14) for a
review) via the respiratory and gastrointestinal tracts (15).
These proteins, together with other plant protein families
(cereal prolamins, a-amylase/trypsin inhibitors, 2S albumins,
puroindolines, etc.) constitute the prolamin superfamily, the
largest group of allergenic proteins in plants (16).
Parietaria (Pj) is one of the major sources of allergens in
the Mediterranean area whose allergenic composition has
been studied in detail identifying three independent families
of proteins with allergenic activity: LTPs (Par j 1 and Par j
2), calcium-binding protein (Par j 4) and profilin (Par j 3)
(17). Among them, LTPs represent the major elicitors of the
IgE response in humans (18). By molecular cloning, it has
been demonstrated that this pollen contains at least three
LTP isoforms with allergenic activity (17, 19, 20). In particu-
lar, the Par j 1 allergen family is composed of Par j 1.0101, a
protein of 139 aa (21), as well as a shorter variant, Par j
1.0201, composed of 102 aa (22). The coding regions of the
Par j 1.0102 and Par j 1.0201 isoforms show 95% identity at
the amino acid level within the first 97 amino acids. Overall,
the two isoforms differ by the presence of a 37 amino acid
COOH-terminal tail in the Par j 1.0101 allergen.
Based on this, the aim of this study was to investigate the
biochemical characteristics of the COOH-terminal region of
the Par j 1.0101 allergen. The potential of such a region to
modulate in vitro and in vivo immune responses was also
explored.
Materials and methods
In silico analysis
Amino acid analysis of the C-terminal region of the Par j
1.0101 allergen (named Par37) was performed using the pre-
diction software of the antimicrobial peptide database (APD)
(http://aps.unmc.edu/AP/main.php)(23).
The synthetic peptide covering the carboxyl-terminal
region of the Parj1.0101 allergen (from amino acids 103 to
139) used in the present work was prepared by ChemPep
(Miami, FL, USA) (Par37 LPVSLRHGPVTGPSDPAHKAR
LERPQIRVPPPAPEKA). An unrelated peptide (the NH2
terminal region of Par j 1.0101 from aa 10 to 35) was used as
a negative control.
Dansyl polymyxin B binding inhibition experiments
Fluorescence experiments were carried out on a JASCO FP
6500 Spectrofluorimeter. Dansyl polymyxin B (DPX) was
purchased from Molecular Probes (INVITROGEN, Milan,
Italy). Binding assays were performed by recording the fluo-
rescence emission spectra of samples containing DPX
[2.5 mM] and after the addition of LPS [1 lg/ml] (E. coli,
strain 026:B6, SIGMA, Milan, Italy). Finally, the fluorescence
intensity was measured after the addition of increasing
amounts (2.5, 5, 12.5, 25 and 50 mM) of Par37. Further
details are provided in the supporting information section.
RNA preparation and RT-PCR
The mouse macrophage-like cell line RAW264.7 was cultured
in RPMI-1640 medium (Invitrogen-Gibco, Milan, Italy) con-
taining either LPS alone [1 lg/ml] or LPS preincubated with
the Par37 peptide [2.5 mM] in 10 ll of medium at R.T for
10 min. The cells were then cultured for 2 h (for transcription
assay) or 6 h (for ELISA assay) at 37°C under 5% CO2.
Primers for murine IL-6, TNF-a and HPRT (internal control)
were obtained from SABioscience (QIAGEN, Milan, Italy).
Details for cell culture, RNA preparation and RT-PCR anal-
ysis are provided in the supporting information section.
ELISA
Supernatants from the mouse macrophage-like cell line
RAW264.7 cultured as described above were collected and
stored at 20°C for cytokine analysis. Levels of IL-6 and
TNF-a cytokines were determined by sandwich ELISA kits,
according to the manufacturers’ instructions (BD Biosciences
Pharmingen, San Jose, CA, USA). The sensitivity of each
assay was 4 pg/ml (IL-6) and 8 pg/ml (TNF-a).
Recombinant proteins for mouse immunization
Recombinant allergens were expressed as His-tagged proteins
(pQE30 vector) in the M15 strain (QIAGEN, Milan, Italy).
Induction and purification protocols were conducted as pre-
viously described (24). Recombinant proteins were tested for
endotoxin content using the Multi-test Limulus Amebocyte
Lysate (LAL) pyrogen plus test (Bio-Whittaker, VWR Interna-
tional, Milan, Italy) (the endogenous endotoxin content was
 0.003 ng LPS/lg of recombinant protein). Further details
are provided in the Supporting information section.
Immunization protocol
Eight-week-old female Balb/c mice (Charles River, Milan,
Italy) (n = 10) were injected intraperitoneally (i.p.) with 2 lg/
mouse of purified rPar j 1.0101 or rPar j 1.0201 as previously
described (25) Mice were bled from the retro-orbital venous
plexus on day 28. Individual sera were stored at 20°C until
analysis. On day 35, mice were killed to collect spleen for cell
response analysis. Further details are provided in the sup-
porting information section.
Measurements of antigen-specific antibody and cell responses
Antibody responses by individual mice against the two
recombinant allergens were monitored by ELISA as previ-
ously described (25). Briefly, plates (Greiner Bio-One,
Frickenhausen, Germany) were coated with either rPar j
1.0101 or rPar j 1.0201 (5 lg/ml). Serum samples were
diluted 1 : 1000 for specific IgG1 and 1 : 50 for specific
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IgG2a evaluation. Results were expressed as OD measured at
490 nm. Proliferation assays were performed on individual
spleen cells as previously reported (25), by adding rPar j
1.0101 or rPar j 1.0201 (10 lg/ml) to cultures. The results
were expressed as S.I. Further details are provided in the
supporting information section.
IFN-c inhibition assay
Mouse spleen cells from na€ıve Balb/c mice and PBMC from
normal subjects (n = 4) were cultured in the presence (posi-
tive control) or absence (negative control) of 1 lg/ml of LPS
(E. coli, strain 026:B6, SIGMA; Milan, ITALY). IFN-c
secretion in the supernatants was determined by ELISA fol-
lowing the manufacturer’s instructions (GE Healthcare,
Milan, Italy). Further details are provided in the Supporting
information section.
Results
Structural analysis
In silico analysis showed that Par37 displays several features
common to antimicrobial peptides (23). This domain contains
a very high proline content (25%), a net positive charge (+3)
and a total hydrophobic ratio of 29%. The protein binding
potential of Par37 calculated using the Boman index gave a
value of 2,06 kcal/mol (Fig. 1).
Inhibition of Polymyxin B binding
Figure 2 shows the emission spectra obtained from solutions
containing DPX+LPS in the presence of increasing amounts
of Par37. As shown, the addition of increasing quantities of
Par37 in solution caused a gradual quenching of fluorescence,
demonstrating that Par37 was capable of displacing the LPS
molecules bound to the DPX. At a concentration of Par37
equal to 50 mM, nearly all the LPS molecules were displaced
and the intensity was almost restored to its initial value.
Experiments performed using a control peptide with a differ-
ent amino acid composition did not shown any decrease in
fluorescence intensity as a function of peptide concentration
(Figure S1).
Mouse cytokine inhibition assays
Raw 264.7 cells were incubated with LPS and Par37-LPS
complexes. Real-time PCR analysis demonstrated that Par37
significantly inhibited LPS-induced IL-6 transcription
(P  0.40) (Fig. 3 panel A). A similar behaviour was
observed for TNF-a expression where a clear trend of inhibi-
tion was observed (P = 0.50) (Fig. 3 panel B). Using ELISA
A 1 85
Parj1.0101 QETCGTMVRALMVRALMPCLPFVQGKEKEPSKGCCSGAKRLDGETKTGPQRVHACECIQTAMKTYSDIDGKLVSEVPKHCGIVDS
Parj1.0201  EETCGTVVGALMPCLPFVQGKEKEPSKGCCSGAKRLDGETKTGPQRVHACECIQTAMKTYSDIDGKLVSEVPKHCGIVDSKLPPI
86 139
Parj1.0101 KLPPIDVNMDCKTVGVVPRQPQLPVSLRHGPVTGPSDPAHKARLERPQIRVPPPAPEKA
Parj1.0201  DVNMDCKTLGVLHYKGN
B 1 37
LPVSLRHGPVTGPSDPAHKARLERPQIRVPPPAPEKA
Molecular Weight = 3918.614 Dalton
Total hydrophobic ratio = 29 %
Total net charge = +3
Percentage of proline residues = 25 %
Protein-binding Potential (Boman index) is: 2.06 kcal/mol
Figure 1 In silico analysis. Panel A shows the amino acid alignment
of the sequences of the Par j 1.0101 and Par j 1.0201 isoforms in sin-
gle letter code. The sequence in bold within the Par j 1.0101 allergen
highlights the COOH-terminal region. Panel B shows the properties
of the Par37 peptide detected using the algorithm supplied by the
antimicrobial peptide database (http://aps.unmc.edu/AP/about.php).
λ (nm)
350 400 450 500 550
Fl
uo
re
sc
en
ce
 in
te
ns
ity
 (a
rb
. u
n.
)
0
50
100
150
200
DPX 
LPS
[Par37] 2.5 mM
[Par37] 5 mM
[Par37] 12.5 mM
[Par37] 25 mM 
[Par37] 50 mM 
[Par37] (mM)
0 10 20 30 40 50
Fl
uo
re
sc
en
ce
in
hi
bi
tio
n 
(%
)
0
20
40
60
80
100
Figure 2 Inhibition of polymyxin B binding. Fluorescence spectra
performed on a solution containing 2.5 mM DPX before (solid line)
and after (dotted line) addition of LPS (1 lg/ml). Increasing aliquots
of Par37 peptide [2.5 mM (empty squares), 5 mM (solid circles),
12.5 mM (empty circles), 25 mM (solid triangles) and 50 mM
(empty triangles)] were successively added to the same sample.
The percentage of fluorescence intensity inhibition obtained after
each addition of Par37 peptide is shown in the inset. The continu-
ous line represents the best fit of the data.
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assays, we observed that Par37 preincubation strongly
reduced LPS-induced IL-6 production (P < 0.40). TNF-a
determination also showed reduced production in all the
tested samples.
Inhibition of IFN-c production from human PBMC and
murine spleen cells
To determine whether addition of the Par37 peptide has any
effect on LPS-induced IFN-c production, human PBMC and
murine spleen cells were stimulated with different premixed
LPS-Par37 solutions. Preincubation of Par37 with LPS signifi-
cantly reduced IFN-c production in a dose dependent manner
when compared to a culture control with LPS alone (Figs 4
and 5). In addition, Par37 alone had no effects on IFN-c pro-
duction by mouse spleen cells and human PBMC. These data
provide evidence that Par 37 acts efficiently as an inhibitor of
the human and mouse immune response to endotoxins.
Mouse antibody and cell responses to rPar j 1 isoforms
Different groups of Balb/c mice were immunized with either
the rPar j 1.0101 or rPar j 1.0201 isoforms. Serum IgG sub-
classes and spleen cell responses were evaluated against both
Par j 1 isoforms. Immunization with rPar j 1.0101 induced
strong IgG1 and IgG2a responses, which bound both rPar j
1.0101 and rPar j 1.0201 with comparable efficiency in
ELISA assays. On the other hand, when mice were immu-
nized with the shorter isoform lacking Par37 (Par j 1.0201),
very low levels of IgG1 antibodies and barely detectable
IgG2a antibodies were induced, which were in all cases at
significantly lower levels than those obtained after rPar j
1.0101 immunization (P < 0.01). This highly significant dif-
ference was observed for both IgG1 and IgG2a subclasses,
and regardless of the antigen used in the ELISA assay
(Fig. 6, panels A and B). Slight differences in spleen cell
responses were found depending on the antigen used in the
proliferation assay. In particular, when rPar j 1.0101 was
added to in vitro re-stimulated immune spleen cells, signifi-
cantly higher S.I. values (P < 0.05) were observed in rPar j
1.0101-immunized mice compared with rPar j 1.0201-immu-
nized animals (Fig. 6, panel C). Conversely, re-stimulation
with the shorter rPar j 1.0201 isoform generally induced
lower S.I. levels, but they were comparable in both groups of
mice (Fig. 6, panel C).
Discussion
The mechanisms by which a subject becomes sensitized to cer-
tain proteins rely on a series of interactions within the immune
Figure 3 Effects of Par37 on IL-6 and TNF-a transcription and
secretion in Raw 264.7 cells. Panels A and B show real-time PCR
analysis performed 2 hours after LPS induction. Panels C and D dis-
play ELISA assays performed on culture supernatants 6 hours after
LPS induction. The values shown are means  SEM. Statistical
analysis was performed comparing the cells treated with 1 ng/ml of
LPS versus cells treated with the same concentration of antigen
preincubated with LPS-Par37. Bars show statistical significance.
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system, which are not well understood. In addition to genetic
factors, different triggering agents in the environment may be
responsible for the induction of the allergic reactions.
In this study, we focused our attention on the characteriza-
tion of a region of the major Parietaria Par j 1.0101 allergen,
which has not been found in any other plant LTP. This
COOH-terminal region (named Par37) presents biochemical
features of peptides involved in host defence including a high
percentage of proline residues, a high ratio hydrophobic resi-
dues and a net positive charge. When isolated from the full-
length allergen and used as a synthetic peptide, the Par37
peptide showed LPS-binding activity and was capable of
influencing LPS-mediated signalling in vitro. By means of
real-time PCR and ELISA assays, we were able to show that
LPS-induced IL-6 and TNF-a expression were inhibited at
both the transcriptional and translational level in the
RAW264.7 cell line after preincubation with Par37. This
inhibitory effect was confirmed when spleen cells from na€ıve
Balb/c mice and human PBMC were examined for their abil-
ity to secrete IFN-c after LPS induction. In these experimen-
tal settings, the Par37 peptide showed an ability to reduce
cytokine production in a dose responsive manner. No cyto-
kine production was induced by the peptide per se either in
the murine or in the human assays. Taken together, these
data demonstrated that the Par 37 peptide can bind and
sequester LPS interfering with the physiological response to
endotoxin.
The identification of an LPS-binding region within the
Par j 1.0101 allergen raises the question whether this bind-
ing can modulate the immune response. For instance, a
recently published paper reported that the presence of a
very low level of contaminating LPS can influence the
immune response to HDM (26). To further understand the
immunological properties of the Par37 peptide, Balb/c mice
were injected i.p. with either of the two isoforms of the
Par j 1 allergen characterized by the presence (Par j
1.0101) or absence (Par j 1.0201) of the Par37 peptide.
Immunization studies demonstrated that the Par j 1.0201
isoform did not give rise to detectable levels of IgG anti-
bodies capable of recognizing both rPar j 1 isoforms.
Accordingly, only immunization with the rPar j 1.0101
(encompassing the Par37 sequence) was able to induce an
antibody response and spleen cell proliferation in response
to in vitro re-stimulation with the same antigen. Starting
from the observation that both allergens were tested for
LPS contamination, we cannot address the question
whether this behaviour is associated with the Par37’s bio-
chemical characteristics or its ability to bind tiny undetect-
able amounts of LPS. Another future question to elucidate
will be to understand whether the Par j 1.0101 isoform
may have immunological effects different from those
induced by Par j 1.0201 in clinical settings.
In conclusion, the data reported in this study demonstrate
that one isoform of the major Parietaria allergen (Par j
1.0101) displayed LPS-binding activity due to the presence
of a short COOH-terminal domain and that this region
showed immune modulatory activity influencing cytokine
and antibody responses in vitro and in vivo.
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Figure 5 Human IFN-c cytokine inhibition assay. ELISA assay inhi-
bition of IFN-c cytokine release by PBMC from healthy subjects
after stimulation with LPS or LPS preincubated with increasing
concentrations of the Par37 synthetic peptide. The values on the
x-axis indicate the relative concentrations of the antigens used. Val-
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Figure 4 Mouse cytokine inhibition assays. INF-c cytokine
release by spleen cells from na€ıve Balb/c mice after in vitro stim-
ulation under different conditions: no stimulus, Par37 alone, LPS
alone and LPS after preincubation with increasing concentrations
(0.25 and 2.5 lM) of the Par37 synthetic peptide. Preincubation
with the highest concentration of Par37 (2.5 lM) significantly
inhibited IFN-c release (P < 0.05). Bars represent mean  SEM
of data from four independent experimental replicates.
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